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Context:MEN1 gene alterations have been implicated in lung carcinoids, but their effect on gene
expression and disease outcome are unknown.
Objective: To analyse MEN1 gene and expression anomalies in lung neuroendocrine neoplasms
(NENs) and their correlations with clinicopathologic data and disease outcome.
Design: We examined 74 lung NENs including 58 carcinoids and 16 high-grade neuroendocrine
carcinomas (HGNECs) forMEN1mutations (n70) and allelic losses (n69), promoter hypermeth-
ylation (n65), and mRNA (n74) expression. Results were correlated with disease outcome.
Results:MEN1mutations were found in 7/55 (13%) carcinoids and in 1 HGNEC, mostly associated
with loss of the second allele.MEN1 decreased expression levels correlated with the presence of
mutations (P0.0060) and was also lower in HGNECs than carcinoids (P0.0024). MEN1 methyl-
ation was not associated with mRNA expression levels. Patients with carcinoids harbouringMEN1
mutation and loss had shorter overall survival (P0.039 and P0.035, respectively), and lowMEN1
mRNA levels correlated with distant metastasis (P0.00010) and shorter survival (P0.0071). In
multivariate analysis, stage andMEN1 allelic loss were independent predictors of prognosis.
Conclusion: Thirteen percent of pulmonary carcinoids harbour MEN1 mutation, associated with
reduced mRNA expression and poor prognosis. Also in mutation-negative tumours, low MEN1
gene expression correlates with an adverse disease outcome. Hypermethylation was excluded as
the underlying mechanism.
Pulmonary neuroendocrine neoplasms (NENs) includewell differentiated carcinoids, classified into typical
(TCs) and atypical (ACs) subtypes, with a relatively fa-
vorable prognosis (1, 2), and aggressive high-grade neu-
roendocrine carcinomas (HGNECs), ie, large cell neu-
roendocrine carcinoma (LCNEC) and small cell lung
cancer (SCLC) .
Lung carcinoids occur in 5% of patients with multiple
endocrine neoplasia (MEN) type 1 syndromewithMEN1
germline mutations (3). MEN1 mutations have been re-
ported in approximately 16% of sporadic lung carcinoids
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(4–6), but are exceptional inHGNECs (7, 8).Allelic losses
of theMEN1 locus are detected more frequently (36%)
than genemutations (5), suggesting that alternativemech-
anisms might lead toMEN1 gene inactivation. So far, the
association of MEN1 gene alterations with clinical fol-
low-up has not been reported in lung NENs.
Here we report a comprehensive analysis ofMEN1 al-
terations, methylation status and transcriptional expres-
sion in 74 lung NENs. Results are compared with tumor
characteristics and clinical outcome.
Materials and Methods (detailed in
Supporting Information)
Tissue samples
Seventy-four sporadic lung NENs (34 TCs, 23 ACs, 1 un-
classified carcinoid, 9 LCNECs, 6 SCLCs and 1 mixed LCNEC-
SCLC), including 71 with follow-up (median 52 months) were
studied. Institutional review board approval for the study was
obtained by each contributing center following local ethical re-
quirements. Nine neuroendocrine cell lines were included for
MEN1 mRNA expression analysis.
MEN1 mutational analysis
The entire coding region and splice junctions ofMEN1were
analyzed on tumor and matched normal DNA by Sanger se-
quencing, as described (9) (Supplementary Table 1A).
MEN1 deletion analysis
Fluorescent in situ hybridization on frozen sections was per-
formed using the MEN1 locus BAC-probe CTD-222019, and
centromere probes for chromosomes 1, 11, 3 and 7 as described
(10).
Quantitative real-time PCR (QRT-PCR)
QRT-PCR was performed using mRNA on MEN1, menin
interactors JUND andMLL, and menin targets HOXC8, P18,
P21, P27, using primers listed in Supplementary Table 1B. Ex-
pression levels were normalized toACTB andCYPA housekeep-
ing genes as described (11).
Methylation-Specific PCR (MSP) and next-
generation sequencing (NGS)
MEN1 promoter methylation analysis was performed on all
cases by nestedMSP (Supplementary Table 1C) and by NGS on
Methyl-CpG-binding Domain (MBD)-immunoprecipitated
DNA of 10 primary carcinoids and carcinoid cell lines NCI-
H720 and NCI-H727 (focusing on the MEN1 gene).
Statistical analysis
Correlations betweenMEN1 data and follow-up were deter-
mined using IBM SPSS Statistics (v20.0.0; IBM) setting the P-
values cut-off for significance at  0.05. Differences in mean
MEN1mRNA levelswere determined by Student’s t test, and the
optimal cut-off pointwas determined using area under theROC-
curve analysis. Associations between clinical and molecular pa-
rameters were calculated using logistic and linear regression,
Fisher’s exact or 2 tests, as appropriate. Associations between
relative expression levels ofMEN1 and other genes were calcu-
lated using Pearson’s correlation.
Survival curves were created by the Kaplan-Meier method
and compared using the log-rank test. The prognostic value of
age at diagnosis, histopathology, sex, smoking status, tumor di-
ameter andMEN1mutation, deletion and gene expression were
tested in univariate and multivariate settings using Cox-regres-
sion.Only variables with aP-value 0.10 in univariate analyses
were included in multivariate analyses.
Results
MEN1 gene mutations and deletions are more
frequent in ACs
MEN1mutations were searched in 70 tumors, includ-
ing 7 previously published cases (5). Eight cases (11%)
showed nonsynonymous somatic alterations: 2/32 TCs
(6%), 5/23 ACs (22%) and 1/7 LCNECs (14%). Muta-
tions included three small deletions, three single nucleo-
tide substitutions and two insertions (Supplementary Ta-
bles 2 and 3). patient 35 showed the same MEN1
mutations in the primary tumor and two distant metas-
tases removed eight and ten years later.
Ploidy status and MEN1 deletion were analyzed by
FISH in 69 tumors (Table 1B and Figure 1A-C). Most
carcinoidswere disomicwhereasHGNECsweremore fre-
quently polysomic. Among carcinoids, 8/57 (14%, 1 TC
and 7 ACs) showed MEN1 allelic loss. In HGNECs,
MEN1 was deleted in 3/12 cases (25%).MEN1 deletion
was more frequent in ACs than in TCs (P  .0060), and
was significantly associated with presence of mutations in
both the total group of NENs (P  .0022) and in carci-
noids (P  .0063) (Supplementary Table 3).
MEN1 gene expression is heterogeneous in lung
NENs
Quantitative RT-PCR performed on all 74 NENs
showed that relative MEN1 expression levels in lung
NENs ranged from 0.031 to 0.85, generally lower than
exocrine pancreas (mean 0.58; Figure 1D) but higher than
normal lung (mean 0.078). A gradual decrease in mean
MEN1 expression values was apparent from TCs to ACs
andHGNECs (Figure 1D-E). Similarly,MEN1 expression
levels in SCLCNCI-H69andLCNECNCI-H460cell lines
were lower than in lung carcinoid NCI-H720 and NCI-
H727 cells (Figure 1D). MEN1 gene expression levels
were inversely correlated to the presence ofmutations and
deletions (Supplementary Table 3) in the complete group
of lung NENs (P  .0060) and carcinoids (P  .025).
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No correlation between MEN1 methylation and
gene expression
As lowMEN1 expression levels were present in tumors
with neither MEN1 mutation nor deletion, we analyzed
MEN1 promoter methylation by MSP. No methylation-
specific product was seen in 65 primary NENs, cell lines
and 15 normal lungs from noncancer patients. NGS in 10
primary carcinoids and lung carcinoid cell lines NCI-
H720andNCI-H727 showed somemethylation signals in
MEN1 promoter region and gene body, but not at the
locus used forMSP analysis (Supplementary Figure 1). No
methylation signals were found in CpG-islands. There
were no differences in methylation between samples with
high and low MEN1 mRNA levels.
Deregulation of MEN1 is associated with
metastasic disease and poor prognosis
MEN1 gene mutations and deletions and decreased
gene expression were associated with the presence of dis-
tant metastasis in both the total group of NENs and the
carcinoids subgroup, but were not related to sex, age and
smoking status (Supplementary Table 4). In particular,
MEN1 mRNA levels were significantly lower in patients
with distant metastasis and/or patients who died from
their tumor, both in the entire group (0.162 vs. 0.318,P
.00080) and within the carcinoid subgroup (Figure 1E).
Univariate survival analysis showed in both the com-
plete group ofNENs and the carcinoid subgroup that age,
histopathology, stage, presence of MEN1 deletions and
decreased gene expression were significantly associated
with higher risk of death (Table 1). At multivariate sur-
vival analysis, histopathology and decreasedMEN1 gene
expression in lung NENs overall, and stage and MEN1
deletion in the carcinoid subgroup retained statistical sig-
nificance. Kaplan-Meier survival analysis confirmed that
the 15-year overall survival of lung carcinoids was signif-
icantly shorter in patients with MEN1 mutation (Figure
1F), decreasedmRNA levels (Figure 1G) anddeletion (P
.035).
Menin interactors and target genes
Within the complete set of NENs,MEN1 gene expres-
sionwas correlatedwith that of its interactors JUND (P
.016) andMLL (P .026) but not of its targetsHOXC8,
P18, P21 and P27. Significant associations between
MEN1 deletion and low HOXC8 expression (P  .010)
and low P18 gene expression (P .017) were also found.
MEN1 mutational status and menin protein expression
were not associated with mRNA levels of interactors and
downstream targets.
In the complete group of NENs, as well as within car-
cinoids, lower levels ofP18 expression (P .0074andP
.0011, respectively) were associated with lower 15-year
survival.
Discussion
Our studyonpulmonaryNENs shows that the presence of
MEN1mutation and/or a lowerMEN1 gene expression is
associated with distant metastasis and lower 15-year sur-
vival, in both the entire cohort of NENs and lung carci-
noids considered separately.
MEN1 mutations were found in 13% (7/55) of carci-
noids, in line with previous reports (4, 5), with most mu-
tations occurring in ACs. All mutations were of the loss of
function type, and most mutated cases also displayed de-
letion of the second MEN1 locus. Only 1/15 HGNECs
was mutated, confirming that MEN1 mutations do not
play a major role in HGNECs (7, 8).
The largemajority of neoplasmswithwild-typeMEN1
gene had high mRNA levels. However, not all cases with
low mRNA levels harbored mutations or deletions, indi-
cating that othermechanismsmight unbalanceMEN1 ex-
Table 1. Univariate and multivariate analysis of clinical data and MEN1 parameters correlated with outcome of
patients with pulmonary neuroendocrine neoplasms (NENs)
A) Lung NENs B) Carcinoids
Univariate Multivariate* Univariate Multivariate*
P-value P-value P-value P-value
Age at diagnosis 0.0003 NS 0.0021 NS
Diameter 0.086 NI NS NI
Histopathology <0.0001 <0.0001 0.011 NS
Sex 0.049 NS NS NI
Smoking status NS NI NS NI
Stage 0.0002 NS 0.0013 0.0009
MEN1 deletion 0.013 NS 0.047 0.013
MEN1 mutation 0.060 NI 0.050 NI
MEN1 gene expression 0.0068 0.017 0.035 NS
*Only parameters displaying a P-value 0.05 are included in multivariate analysis and in the final model all P-values needed to be 0.05.
Abbreviations used: NEN: neuroendocrine neoplasm; NI, not included in multivariate analysis; NS, not significant
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pression in these tumors. No hypermethylation was seen
at CpG-islands within theMEN1 promoter at MSP-anal-
ysis, while methylated regions outside the CpG-island
were identified by MBD-sequencing. However, such
methylation was not associated with reduced MEN1
mRNA levels, suggesting that
MEN1 hypermethylation unlikely
underlies MEN1 downregulation.
MEN1 gene alterations and re-
duced expression were significantly
associated with tumor stage, pres-
ence of distant metastases, and pa-
tient survival. At multivariate anal-
ysis, decreased MEN1 gene
expression was an independent pre-
dictor of disease outcome in both the
complete group of NENs and in the
group of carcinoids alone. This find-
ing seems specific for lung NENs
since it is not observed in pancreatic
NENs (10, 14).
The mechanisms underlying the
role of MEN1 gene loss of function
and the acquisitionof clinical aggres-
siveness in lung carcinoids deserves
further investigation. We identified
correlations between MEN1 and
JUND/MLL mRNA levels, but not
with menin targets P18, P21 and
P27, suggesting that lung-specific
mechanisms might be active, such as
the E-cadherin/-catenin pathway
which interacts with menin and is
frequently deregulated in lungNENs
(7, 15, 16).
In conclusion, our comprehensive
overview ofMEN1 molecular alter-
ations in lung NENs demonstrates a
significant association between
MEN1 gene deregulation and clini-
cal aggressiveness in lung carcinoids
and postulates different mechanisms
of gene regulation inwell and poorly
differentiated NENs.
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